Apple Inc. (AAPL), Q32 Bio (QTTB) and CSX Corp. (CSX) each climbed to fresh 52-week highs on Monday as investors looked beyond broader market concerns and focused on earnings potential, clinical progress and improving industry conditions.

Q32 Bio stock jumped 90%, while Apple and CSX stocks ended the session 0.6% and 0.4% higher, respectively.

Apple Hits Record High As Citi Raises Price Target Ahead Of Earnings 

reached a new all-time high of $323.45, extending its two straight weeks of gains after receiving renewed optimism from Wall Street analysts.

Citi increased its target price on Apple shares to $365 from $315 while reiterating its ‘Buy’ rating. The firm believes Apple is in a strong position ahead of its fiscal Q3 earnings and can continue growing its market share even as overall device sales slow.

According to Citi, the higher price target reflects improved margin expectations following Apple's recent product price increases.

Despite the smartphone industry slowdown, Apple saw its smartphone  rise 3% year-on-year in Q2, according to Counterpoint Research. Apple captured a record 20% share of the global market in the quarter, helped by strong demand for its iPhone 17 lineup.

On Stocktwits, retail sentiment around the stock turned to ‘neutral’ from ‘bearish’ the previous day.

Q32 Bio Surges After Promising Hair Loss Drug Trial Results 

delivered the session's biggest move, hitting a 19-month high of $22.50 after reporting encouraging Phase 2a data for bempikibart in patients with severe alopecia areata (hair fall). The experimental anti-IL-7Rα therapy produced meaningful improvements in hair regrowth, including a 40% SALT-20 (a standard tool for measuring alopecia severity) response after 36 weeks.

The company also outlined plans to pursue a registration-directed development program by the first half of 2027 and announced a $200 million public stock offering to help finance future clinical development.

After the data, Wells Fargo analyst Derek Archila upgraded Q32 Bio to ‘Overweight’ from ‘Equal Weight’ and raised the price target sharply from $10 to $66. The firm said the trial results increased its confidence that bempikibart could succeed as a treatment.

The firm also believes Q32 Bio could grow significantly, potentially reaching a market value of about $2 billion after the company strengthens its financial position. Retail sentiment around the stock remained in ‘extremely bullish’ territory.

CSX Hits Record High As Raymond James Raises Price Target 

CSX stock reached a record high of $49.90 after Raymond James raised its price target on CSX to $56 from $49 and maintained an ‘Outperform’ rating.

The firm expects the transportation company to report stronger fiscal second-quarter (Q2) results, citing operational improvements and a better setup in the freight market.

According to Raymond James, the transportation sector is benefiting from tighter supply conditions even though overall demand remains relatively soft. The firm believes this imbalance could create a more favorable environment for rail operators as industry conditions continue to stabilize.

However, retail sentiment toward the stock turned from ‘bearish’ to ‘neutral’ in a day.

So far this year, AAPL and CSX stocks have gained 16% and 36%, respectively, while QTTB stock has surged 543%.